Real World Study on the Use of Cemiplimab in Adult Patients in UK (REACT-CEMI)

NCT05493826 COMPLETED

The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.

Details

Lead sponsor	Sanofi
Status	COMPLETED
Enrolment	110
Start date	Mon Jul 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cutaneous Squamous Cell Carcinoma

Interventions

• No intervention

Countries

United Kingdom